THE SAFETY OF GLUCOCORTICOIDS IN THE TREATMENT OF  INFAMMATORY RHEUMATIC DISEASE: A SYSTEMATIC REVIEW

Nella Rossiyah

doi:10.53555/nnmhs.v9i3.1623

Authors

Nella Rossiyah Faculty of Medicine, University of Jambi, Indonesia Author

DOI:

https://doi.org/10.53555/nnmhs.v9i3.1623

Keywords:

Arthritis, Glucocorticoids, Infammatory rheumatic disease, Prednisone

Abstract

Glucocorticoids have been utilized as a component of the treatment for rheumatoid arthritis ever since their introduction some decades ago. It has been established that glucocorticoids are effective in lowering the inflammatory activity induced by this condition and in slowing the course of erosive joint degradation. Both of these benefits can be attained by taking the medication. Unfortunately, they also have a wide variety of potentially adverse consequences, the severity of which may vary depending on the dosage and the length of the therapy. Nevertheless, the benefits of these medications far outweigh the risks associated with them. As a result of the rise in popularity of many alternative therapy alternatives, the use of glucocorticoids as a treatment method is currently being debated (such as biologic and targeted synthetic diseasemodifying antirheumatic medicines). It is possible to provide corticosteroids by injecting them directly into the joint. Many people are opposed to the use of glucocorticoids because of the dose-dependent adverse effects that they can have, despite the fact that they continue to be an essential component in the treatment of a wide variety of inflammatory rheumatic diseases. The usage of glucocorticoids for an extended period of time is connected with a greater risk of experiencing adverse consequences. These problems are associated with an increased chance of developing cardiovascular disease, diabetes, and possibly mortality.

References

Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Am Coll Rheumatol. 2020;72(2):220– 33.

Becker JA, Daily JP, Pohlgeers KM. Acute Monoarthritis: Diagnosis in Adults. Am Fam Physician. 2016 Nov;94(10):810–6.

Ma L, Cranney A, Holroyd-Leduc JM. Acute monoarthritis: what is the cause of my patient’s painful swollen joint? C Can Med Assoc J = J l’Association medicale Can. 2009 Jan;180(1):59–65.

Selmi C, Gershwin ME. Diagnosis and classification of reactive arthritis. Autoimmun Rev. 2014;13(4–5):546–9.

Firestein GS, Budd RC, Harris ED, McInnes IB, Ruddy S, Sergent JS. KELLEY ’ S Textbook of Rheumatology. Goldring MB, editor. philadelphia; 2009 p. 37–60.

FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744–60.

Hazes JMW, Luime JJ. The epidemiology of early inflammatory arthritis. Nat Rev Rheumatol. 2011 Jun;7(7):381– 90.

Singh JA, Gaffo A. Gout epidemiology and comorbidities. In: Seminars in arthritis and rheumatism. Elsevier; 2020. p. S11–6.

Juraschek SP, Miller ER 3rd, Gelber AC. Body mass index, obesity, and prevalent gout in the United States in 19881994 and 2007-2010. Arthritis Care Res (Hoboken). 2013 Jan;65(1):127–32.

Luís M, Boers M, Saag K, Buttgereit F, da Silva JAP. The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence. Curr Opin Rheumatol. 2022 May;34(3):179–86.

Boers M, Hartman L, Opris-Belinski D, Bos R, Kok MR, Da Silva JA, et al. Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Ann Rheum Dis. 2022 Jul;81(7):925–36.

Ajeganova S, Svensson B, Hafström I, Group BS. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4(4):e004259.

Listing J, Kekow J, Manger B, Burmester G-R, Pattloch D, Zink A, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415– 21.

Roubille C, Rincheval N, Dougados M, Flipo R-M, Daurès J-P, Combe B. Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. Ann Rheum Dis. 2017;76(11):1797– 802.

Movahedi M, Beauchamp M, Abrahamowicz M, Ray DW, Michaud K, Pedro S, et al. Risk of incident diabetes mellitus associated with the dosage and duration of oral glucocorticoid therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68(5):1089–98.

van der Goes MC. [Low dosed prednisolone in older patients with rheumatoid arthritis] Ned Tijdschr Geneeskd. 2022 Nov;166.

Gupta P; Bhatia V. Corticosteroid Physiology and Principles of Therapy. Indian J Pediatr. 2008;76:1039–44.

Ethgen O, de Lemos Esteves F, Bruyere O, Reginster J-Y. What do we know about the safety of corticosteroids in rheumatoid arthritis? Curr Med Res Opin. 2013;29(9):1147–60.

Hoes JN, Jacobs JWG, Verstappen SMM, Bijlsma JWJ, Van der Heijden G. Adverse events of low-to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833–8.

Sihvonen S, Korpela M, Mustonen J, Huhtala H, Karstila K, Pasternack A. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol. 2006 ;33 (9) :1 740–6.

Bruntol L, Dandan R, Knollmann B. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. Philadelphia: Mc Graw Hill Education; 2018.

Yasir M, Goyal A, Bansal P, Sonthalia S. Corticosteroid adverse effects. 2018;